Canada - English - Health Canada

sandoz canada incorporated - aliskiren (aliskiren fumarate) - tablet - 150mg - aliskiren (aliskiren fumarate) 150mg - renin inhibitors

Canada - English - Health Canada

sandoz canada incorporated - aliskiren (aliskiren fumarate) - tablet - 300mg - aliskiren (aliskiren fumarate) 300mg - renin inhibitors

United States - English - NLM (National Library of Medicine)

prasco laboratories - aliskiren hemifumarate (unii: c8a0p8g029) (aliskiren - unii:502fwn4q32) - aliskiren is indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age and older to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. there are no controlled trials demonstrating risk reduction with aliskiren. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection,

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd - aliskiren, amlodipine - hypertension - agents acting on the renin-angiotensin system - rasilamlo is indicated for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with aliskiren or amlodipine used alone.

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - aliskiren hemifumarate (unii: c8a0p8g029) (aliskiren - unii:502fwn4q32) - aliskiren tablets are indicated for the treatment of hypertension in adults to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. there are no controlled trials demonstrating risk reduction with aliskiren tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihyperten

United States - English - NLM (National Library of Medicine)

lxo us inc. - aliskiren hemifumarate (unii: c8a0p8g029) (aliskiren - unii:502fwn4q32) - aliskiren 150 mg - tekturna is indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age and older to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. there are no controlled trials demonstrating risk reduction with tekturna. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than 1 drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. do not use tekturna with arbs or aceis in patients with diabetes [see warnings and precautions ( 5.2) and clinical studies ( 14.3)]. tekturna is contraindicated in patients with known hypersensitivity to any of the components [see warnings and precautions ( 5.3)]. tekturna is contraindicated in pediatric patients less than 2 years of age because of the risk of high aliskiren exposures identified in juvenile animals due to immaturity of transporters and metabolic enzymes [see use in specific populations ( 8.4)]. risk summary tekturna can cause fetal harm when administered to a pregnant woman. use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death [see clinical considerations] . most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. when pregnancy is detected, discontinue tekturna as soon as possible. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major malformations and miscarriage in clinically recognized pregnancies is 2-4%, and 15-20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage). hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. pregnant women with hypertension should be carefully monitored and managed accordingly. fetal/neonatal adverse reactions use of drugs that act on the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, oligohydramnios, fetal lung hypoplasia and skeletal deformations, including skull hypoplasia, hypotension, and death. in the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. in patients taking tekturna during pregnancy, perform serial ultrasound examinations to assess the intra- amniotic environment. fetal testing may be appropriate, based on the week of gestation. patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. closely observe infants with histories of in utero exposure to tekturna for hypotension, oliguria, and hyperkalemia. if oliguria or hypotension occur in neonates with a history of in utero exposure to aliskiren, support blood pressure and renal perfusion. exchange transfusions or dialysis may be required as a means of reversing hypotension and substituting for disordered renal function. data animal data in developmental toxicity studies, pregnant rats and rabbits received oral aliskiren hemifumarate during organogenesis at doses up to 20 and 7 times the maximum recommended human dose (mrhd) based on body surface area (mg/m 2 ), respectively, in rats and rabbits. (actual animal doses were up to 600 mg/kg/day in rats and up to 100 mg/kg/day in rabbits.) no teratogenicity was observed; however, fetal birth weight was decreased in rabbits at doses 3.2 times the mrhd based on body surface area (mg/m 2 ). aliskiren was present in placentas, amniotic fluid and fetuses of pregnant rabbits. risk summary there is no information regarding the presence of aliskiren in human milk, the effects on the breastfed infant, or the effects on milk production. because of the potential for serious adverse reactions, including hypotension, hyperkalemia and renal impairment in nursing infants, advise a nursing woman that breastfeeding is not recommended during treatment with tekturna. tekturna is contraindicated in patients less than 2 years of age [see contraindications ( 4)]. tekturna is indicated for treatment of hypertension in pediatric patients 6 years of age and older weighing 50 kg or more. the safety and effectiveness of aliskiren have been established in pediatric patients 6 years of age and older weighing 20 kg or more, but tekturna is not approved in patients 6 years of age and older weighing 20 kg to less than 50 kg because of the lack of an appropriate dosage form. use of tekturna in pediatric patients 6 years and older is supported by evidence from a pharmacokinetic trial and two randomized, double-blind clinical trials in pediatric patients with hypertension 6 years to 17 years of age weighing 20 kg or more [see clinical pharmacology ( 12.3), clinical studies ( 14.4 ) ] . the safety and effectiveness of tekturna have not been established in pediatric patients younger than 6 years of age and patients less than 20 kg. avoid use in patients 2 years to less than 6 years and patients weighing less than 20 kg due to the limited information about aliskiren metabolism and exposures in this age group. no data are available in pediatric patients weighing less than 20 kg or in pediatric patients with a glomerular filtration rate <30 ml/min/1.73 m 2 . juvenile animal toxicity data toxicology studies in juvenile animals the approximate human age equivalent of children less than 2 years of age identified 85- to 385-fold increased systemic exposure to aliskiren compared to adult rats. the increased aliskiren exposure in juvenile rats was attributed to immaturity in aliskiren drug transporters and metabolizing enzymes. increased aliskiren exposures were associated with premature deaths. although a definitive pathology-based cause of death could not be ascertained, the premature deaths were attributed to the immaturity in aliskiren metabolism. the nonclinical findings suggest a distinct age-dependent relationship between dose and exposure. neonates with a history of in utero exposure to tekturna if oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. of the total number of patients receiving aliskiren in clinical studies, 1,275 (19%) were 65 years or older and 231 (3.4%) were 75 years or older. no overall differences in safety or effectiveness were observed between these subjects and younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. safety and effectiveness of tekturna in patients with severe renal impairment [creatinine clearance (crcl) less than 30 ml/min] have not been established as these patients were excluded in efficacy trials [see clinical studies ( 14)].

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, amlodipine, hydrochlorothiazide - hypertension - cardiovascular system - rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.

Canada - English - Health Canada

noden pharma dac - aliskiren (aliskiren fumarate); hydrochlorothiazide - tablet - 150mg; 12.5mg - aliskiren (aliskiren fumarate) 150mg; hydrochlorothiazide 12.5mg - renin inhibitors

Canada - English - Health Canada

noden pharma dac - aliskiren (aliskiren fumarate); hydrochlorothiazide - tablet - 150mg; 25mg - aliskiren (aliskiren fumarate) 150mg; hydrochlorothiazide 25mg - renin inhibitors

Canada - English - Health Canada

noden pharma dac - aliskiren (aliskiren fumarate); hydrochlorothiazide - tablet - 300mg; 12.5mg - aliskiren (aliskiren fumarate) 300mg; hydrochlorothiazide 12.5mg - renin inhibitors